Literature DB >> 25437375

Abnormal relationship between GABA, neurophysiology and impulsive behavior in neurofibromatosis type 1.

Maria J Ribeiro1, Inês R Violante2, Inês Bernardino3, Richard A E Edden4, Miguel Castelo-Branco5.   

Abstract

Neurofibromatosis type 1 (NF1) is a neurodevelopmental disorder characterized by a broad spectrum of cognitive deficits. In particular, executive dysfunction is recognized as a core deficit of NF1, including impairments in executive attention and inhibitory control. Yet, the neural mechanisms behind these important deficits are still unknown. Here, we studied inhibitory control in a visual go/no-go task in children and adolescents with NF1 and age- and gender-matched controls (n = 16 per group). We applied a multimodal approach using high-density electroencephalography (EEG), to study the evoked brain responses, and magnetic resonance spectroscopy (MRS) to measure the levels of GABA and glutamate + glutamine in the medial frontal cortex, a brain region that plays a pivotal role in inhibitory control, and also in a control region, the occipital cortex. Finally, we run correlation analyses to identify the relationship between inhibitory control, levels of neurotransmitters, and EEG markers of neural function. Individuals with NF1 showed impaired impulse control and reduced EEG correlates of early visual processing (parieto-occipital P1) and inhibitory control (frontal P3). MRS data revealed a reduction in medial frontal GABA+/tCr (total Creatine) levels in the NF1 group, in parallel with the already reported reduced occipital GABA levels. In contrast, glutamate + glutamine/tCr levels were normal, suggesting the existence of abnormal inhibition/excitation balance in this disorder. Notably, medial frontal but not occipital GABA levels correlated with general intellectual abilities (IQ) in NF1, and inhibitory control in both groups. Surprisingly, the relationship between inhibitory control and medial frontal GABA was reversed in NF1: higher GABA was associated with a faster response style whereas in controls it was related to a cautious strategy. Abnormal GABAergic physiology appears, thus, as an important factor underlying impaired cognition in NF1, in a level and region dependent manner.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Electroencephalography; Gamma-aminobutyric acid; Impulse control disorders; Magnetic resonance spectroscopy; Neurofibromatosis type 1; Prefrontal cortex

Mesh:

Substances:

Year:  2014        PMID: 25437375      PMCID: PMC4777301          DOI: 10.1016/j.cortex.2014.10.019

Source DB:  PubMed          Journal:  Cortex        ISSN: 0010-9452            Impact factor:   4.027


  88 in total

1.  Task switching: a high-density electrical mapping study.

Authors:  G R Wylie; D C Javitt; J J Foxe
Journal:  Neuroimage       Date:  2003-12       Impact factor: 6.556

2.  The categorization of natural scenes: brain attention networks revealed by dense sensor ERPs.

Authors:  Maurizio Codispoti; Vera Ferrari; Markus Junghöfer; Harald T Schupp
Journal:  Neuroimage       Date:  2006-06-05       Impact factor: 6.556

3.  Using a Virtual Classroom environment to describe the attention deficits profile of children with Neurofibromatosis type 1.

Authors:  Yafit Gilboa; Sara Rosenblum; Aviva Fattal-Valevski; Hagit Toledano-Alhadef; Albert Skip Rizzo; Naomi Josman
Journal:  Res Dev Disabil       Date:  2011-07-14

4.  Feature-based attention modulates feedforward visual processing.

Authors:  Weiwei Zhang; Steven J Luck
Journal:  Nat Neurosci       Date:  2008-11-23       Impact factor: 24.884

Review 5.  Clinical manifestations and management of neurofibromatosis type 1.

Authors:  James H Tonsgard
Journal:  Semin Pediatr Neurol       Date:  2006-03       Impact factor: 1.636

Review 6.  Event-related brain potentials in the study of visual selective attention.

Authors:  S A Hillyard; L Anllo-Vento
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

7.  Neurofibromin regulates corticostriatal inhibitory networks during working memory performance.

Authors:  Carrie Shilyansky; Katherine H Karlsgodt; Damian M Cummings; Kyriaki Sidiropoulou; Molly Hardt; Alex S James; Dan Ehninger; Carrie E Bearden; Panayiota Poirazi; J David Jentsch; Tyrone D Cannon; Michael S Levine; Alcino J Silva
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

8.  GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression.

Authors:  Jong H Yoon; Richard J Maddock; Ariel Rokem; Michael A Silver; Michael J Minzenberg; J Daniel Ragland; Cameron S Carter
Journal:  J Neurosci       Date:  2010-03-10       Impact factor: 6.167

9.  Continuous performance test performance in a normative epidemiological sample.

Authors:  C Keith Conners; Jeffery N Epstein; Adrian Angold; John Klaric
Journal:  J Abnorm Child Psychol       Date:  2003-10

Review 10.  GABA estimation in the brains of children on the autism spectrum: measurement precision and regional cortical variation.

Authors:  W Gaetz; L Bloy; D J Wang; R G Port; L Blaskey; S E Levy; T P L Roberts
Journal:  Neuroimage       Date:  2013-05-24       Impact factor: 6.556

View more
  28 in total

1.  Disruption of Critical Period Plasticity in a Mouse Model of Neurofibromatosis Type 1.

Authors:  Mariska van Lier; M Hadi Saiepour; Koen Kole; Juliette E Cheyne; Nawal Zabouri; Thomas Blok; Yi Qin; Emma Ruimschotel; J Alexander Heimel; Christian Lohmann; Christiaan N Levelt
Journal:  J Neurosci       Date:  2020-06-11       Impact factor: 6.167

Review 2.  Sensitization of Ion Channels Contributes to Central and Peripheral Dysfunction in Neurofibromatosis Type 1.

Authors:  Aubin Moutal; Erik T Dustrude; Rajesh Khanna
Journal:  Mol Neurobiol       Date:  2016-05-11       Impact factor: 5.590

3.  Risky Decision Making in Neurofibromatosis Type 1: An Exploratory Study.

Authors:  Rachel K Jonas; EunJi Roh; Caroline A Montojo; Laura A Pacheco; Tena Rosser; Alcino J Silva; Carrie E Bearden
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2017-03

4.  Medial Frontal Lobe Neurochemistry in Autism Spectrum Disorder is Marked by Reduced N-Acetylaspartate and Unchanged Gamma-Aminobutyric Acid and Glutamate + Glutamine Levels.

Authors:  Andreia Carvalho Pereira; Inês R Violante; Susana Mouga; Guiomar Oliveira; Miguel Castelo-Branco
Journal:  J Autism Dev Disord       Date:  2018-05

5.  Diabetic brain or retina? Visual psychophysical performance in diabetic patients in relation to GABA levels in occipital cortex.

Authors:  Mafalda Sanches; Sulaiman I Abuhaiba; Otília C d'Almeida; Bruno Quendera; Leonor Gomes; Carolina Moreno; Daniela Guelho; Miguel Castelo-Branco
Journal:  Metab Brain Dis       Date:  2017-03-30       Impact factor: 3.584

6.  Discriminating between neurofibromatosis-1 and typically developing children by means of multimodal MRI and multivariate analyses.

Authors:  Federico Nemmi; Fabien Cignetti; Christine Assaiante; Stephanie Maziero; Fredrique Audic; Patrice Péran; Yves Chaix
Journal:  Hum Brain Mapp       Date:  2019-05-11       Impact factor: 5.038

7.  Resting GABA concentration predicts inhibitory control during an auditory Go-Nogo task.

Authors:  Chia-Hsiung Cheng; David M Niddam; Shih-Chieh Hsu; Chia-Yih Liu; Shang-Yueh Tsai
Journal:  Exp Brain Res       Date:  2017-10-09       Impact factor: 1.972

Review 8.  Proton Magnetic Resonance Spectroscopy: Relevance of Glutamate and GABA to Neuropsychology.

Authors:  Gabriele Ende
Journal:  Neuropsychol Rev       Date:  2015-08-12       Impact factor: 7.444

Review 9.  An executive functioning perspective in neurofibromatosis type 1: from ADHD and autism spectrum disorder to research domains.

Authors:  Taylor F Smith; Jessica A Kaczorowski; Maria T Acosta
Journal:  Childs Nerv Syst       Date:  2020-07-03       Impact factor: 1.475

10.  Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1.

Authors:  Jonathan M Payne; Belinda Barton; Nicole J Ullrich; Alan Cantor; Stephen J C Hearps; Gary Cutter; Tena Rosser; Karin S Walsh; Gerard A Gioia; Pamela L Wolters; James Tonsgard; Elizabeth Schorry; David Viskochil; Laura Klesse; Michael Fisher; David H Gutmann; Alcino J Silva; Scott J Hunter; Celiane Rey-Casserly; Nancy L Cantor; Anna W Byars; Peter L Stavinoha; Joseph D Ackerson; Carol L Armstrong; Jill Isenberg; Sharon H O'Neil; Roger J Packer; Bruce Korf; Maria T Acosta; Kathryn N North
Journal:  Neurology       Date:  2016-11-09       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.